Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma

NKG2D–NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo

(2016) Saravanan Raju et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

(2014) W.-S. Chang et al.   JOURNAL OF IMMUNOLOGY

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma

(2013) Sungyoul Hong et al.   IMMUNOLOGY LETTERS

Induced IL-17-Producing Invariant NKT Cells Require Activation in Presence of TGF-  and IL-1 

(2013) M. Monteiro et al.   JOURNAL OF IMMUNOLOGY

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

(2012) S. R. Mattarollo et al.   BLOOD

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

(2012) J. Richter et al.   BLOOD

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection

(2010) Famke L. Schneiders et al.   CLINICAL IMMUNOLOGY

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand

(2010) Troels R Petersen et al.   IMMUNOLOGY AND CELL BIOLOGY

Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response

(2009) E Alvarez et al.   GENE THERAPY

NKT-cell help to B lymphocytes can occur independently of cognate interaction

(2008) E. Tonti et al.   BLOOD